YI Q3 2024 Earnings EPS Loss of 0145 Highlights Ongoing Operational Headwinds LIVN Q1 2026 Earnings EPS Surpasses Estimates Amid Modest Stock Decline Verrica Pharmaceuticals VRCA Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Sees Modest Stock Gain RELX Q2 2025 Earnings EPS Edges Past Estimates Amid Steady Performance WPRT Q1 2026 Earnings BetterthanExpected EPS but Stock Declines PDD Q4 2025 Earnings EPS Misses Estimates Amid Competitive Pressures